HMOX1 and cancer: Having established KCL-HO-1i as a small molecule that can target the immunomodulatory function of the PvTAM population we explored KCL-HO-1i as an orally bioavailable immunotherapeutic that would be feasible for daily delivery as an anti-cancer therapeutic.